Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Scancell Holdings plc
  6. Company
    SCLP   GB00B63D3314

SCANCELL HOLDINGS PLC

(SCLP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Managers
Name Title Age Since
Lindy Gillian Durrant Chief Executive Officer & Executive Director 62 2021
Keith Green Director-Finance & Administration - 2016
Gillies O'Bryan-Tear, Dr. Chief Medical Officer 65 2020
Robert Matthew Miller, Dr. Medical Director - 2020
Sally Elizabeth Adams, Dr. Executive Director & Chief Development Officer 59 -
Samantha Paston, Dr. Head-Research - 2019
Members of the board
Name Title Age Since
John C. Chiplin, Dr. Executive Chairman - -
Lindy Gillian Durrant Chief Executive Officer & Executive Director 62 2021
Richard Morley Goodfellow, Dr. Executive Director 70 2018
Sally Elizabeth Adams, Dr. Executive Director & Chief Development Officer 59 -
Martin Henry Diggle Non-Executive Director 58 2019
Ursula M. Ney, Dr. Non-Executive Director 68 2019
Susan Elizabeth Clement Davies Non-Executive Director 58 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 791,917,828 712,503,547 90.0% 0 0.0% 90.0%
Shareholders
NameEquities%
Redmile Group LLC 237,306,384 29.1%
Vulpes Investment Management Pte Ltd. 117,179,029 14.4%
Lindy Gillian Durrant 10,666,308 1.31%
Richard Morley Goodfellow 6,602,663 0.81%
Calculus Capital Ltd. 2,579,841 0.32%
John C. Chiplin 2,000,000 0.25%
CRUX Asset Management Ltd. 784,901 0.096%
Cliff Holloway 100,000 0.012%
Sally Elizabeth Adams 70,255 0.0086%
Matthew Gerard Winston Frohn 58,823 0.0072%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Scancell Holdings plc
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
SCANCELL HOLDINGS PLC55.36%244
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414
ALNYLAM PHARMACEUTICALS, INC.60.47%24 787
PHARMARON BEIJING CO., LTD.63.88%22 950
ICON PUBLIC LIMITED COMPANY41.06%21 917
HANGZHOU TIGERMED CONSULTING CO., LTD3.15%21 537
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.62.43%20 337
BIO-TECHNE CORPORATION56.83%19 541
PPD, INC.37.20%16 494
INCYTE CORPORATION-24.37%14 478
BACHEM HOLDING AG111.88%12 701
NOVAVAX, INC.45.23%12 063
QIAGEN N.V.-2.29%11 717
PRA HEALTH SCIENCES, INC.0.00%10 965
CUREVAC N.V.-50.88%10 301
INTELLIA THERAPEUTICS, INC.139.87%9 589
SYNEOS HEALTH, INC.28.74%9 077